Anixa Biosciences (ANIX) Competitors

Anixa Biosciences has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Century Therapeutics has higher revenue and earnings than Anixa Biosciences. Century Therapeutics is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Century Therapeutics' return on equity of -1.43% beat Anixa Biosciences' return on equity.

In the previous week, Anixa Biosciences and Anixa Biosciences both had 3 articles in the media. Century Therapeutics' average media sentiment score of 0.48 beat Anixa Biosciences' score of 0.34 indicating that Century Therapeutics is being referred to more favorably in the news media.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 4.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 183.33%. Century Therapeutics has a consensus price target of $4.25, indicating a potential upside of 85.59%. Given Anixa Biosciences' higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Century Therapeutics.

Anixa Biosciences has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500.

Niagen Bioscience has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

In the previous week, Anixa Biosciences had 2 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Anixa Biosciences and 1 mentions for Niagen Bioscience. Anixa Biosciences' average media sentiment score of 0.34 beat Niagen Bioscience's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Niagen Bioscience has a net margin of 13.43% compared to Anixa Biosciences' net margin of 0.00%. Niagen Bioscience's return on equity of 21.10% beat Anixa Biosciences' return on equity.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 183.33%. Niagen Bioscience has a consensus price target of $15.00, indicating a potential upside of 211.20%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Anixa Biosciences.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anixa Biosciences has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Immuneering has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Anixa Biosciences is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

In the previous week, Anixa Biosciences had 3 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for Immuneering. Anixa Biosciences' average media sentiment score of 0.34 beat Immuneering's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Immuneering's return on equity of -43.33% beat Anixa Biosciences' return on equity.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 183.33%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 208.99%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Anixa Biosciences.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anixa Biosciences has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500.

Anixa Biosciences has higher earnings, but lower revenue than Cellectis. Anixa Biosciences is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 183.33%. Cellectis has a consensus price target of $6.75, indicating a potential upside of 79.52%. Given Anixa Biosciences' higher probable upside, equities research analysts clearly believe Anixa Biosciences is more favorable than Cellectis.

In the previous week, Anixa Biosciences and Anixa Biosciences both had 3 articles in the media. Anixa Biosciences' average media sentiment score of 0.34 beat Cellectis' score of 0.34 indicating that Anixa Biosciences is being referred to more favorably in the media.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anixa Biosciences has a net margin of 0.00% compared to Cellectis' net margin of -84.92%. Cellectis' return on equity of -69.38% beat Anixa Biosciences' return on equity.